SQ-885

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameSQ-885
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsIntegrin antagonistsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3Integrin
Therapy Area/IndicationsSolid tumoursInflammationEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursInflammationEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A